Reducing protein regulator of cytokinesis 1 as a prospective therapy for hepatocellular carcinoma

Xinran Liu1,2, Yangkai Li3, Lijing Meng1, Xin-Yuan Liu4, Anlin Peng5, Yuchen Chen1, Chengyu Liu1,2, Hong Chen1, Sheng Sun1, Xiaoping Miao6, Yu Zhang1, Ling Zheng7 and Kun Huang1,2

Abstract
Proteins that bind to microtubule are important for cell cycle, and some of these proteins show oncogenic characteristics with mechanisms not fully understood. Herein we demonstrate overexpression of protein regulator of cytokinesis 1 (PRC1), a microtubule-associated regulator of mitosis, in human hepatocellular carcinoma (HCC). Moreover, upregulated PRC1 is associated with lower survival rates of HCC patients. Mechanistically, reducing PRC1 blocks mitotic exit of HCC cells at telophase in a spindle assembly checkpoint independent manner, and acts synergistically with microtubule-associated agents (MTAs) to suppress p53-wt or p53-null HCC cells in a p53- or p14ARF-dependent manner; while overexpressing PRC1 increases the resistance of HCC to taxol. A combined treatment of taxol/shPRC1 results in 90% suppression of tumor growth in subcutaneous HCC xenograft models. In orthotopic xenograft mice, reducing PRC1 significantly alleviates HCC development and hepatic injury. Together, our results suggest a dual-mitotic suppression approach against HCC by combining MTAs with cytokinesis inhibition, which blocks mitosis at both metaphase and telophase.

Introduction
Hepatocellular carcinoma (HCC) results in approximately 600,000 deaths worldwide annually1. Microtubule-targeting agents (MTAs), such as taxanes and epothilones, bind with microtubules, altering their dynamics, triggering the spindle assembly checkpoint (SAC) and preventing cells from entering anaphase, which causes mitotic arrest2. However, because of drug resistance or insensitivity, applications of these chemotherapeutic agents are limited for HCC treatment3.

During MTAs induced mitotic arrest, cancer cells either die or exit mitosis by slipping into G1 phase with mis-segregated chromosomes, displaying increased tumorigenicity and resistance to MTAs4–6. Therefore, targeting mitotic exit represents an important therapeutic approach to overcome MTA insensitivity7,8. Presently, most strategies block mitotic exit at the metaphase-to-anaphase transition via SAC9; unfortunately, reduced SAC activity in cancer cells is commonly found10, new approaches against MTA-resistant cancers are needed.

Protein regulator of cytokinesis 1 (PRC1) is a microtubule binding protein required for the completion of cytokinesis at telophase11. PRC1 was previously identified as a substrate of cyclin-dependent kinase (CDK) and a regulator of mitotic spindle midzone formation12,13. In addition to its essential functions in mitosis, upregulated PRC1 has been observed in bladder and breast cancers11,14. Recently, it has been reported that PRC1 promotes early recurrence of HCC in association with the Wnt/beta-catenin signaling15. However,
whether PRC1 affects cancer development through its role in mitosis is unclear.

Here we demonstrated that PRC1 knockdown inhibits HCC proliferation through blocking cytokinesis in an SAC-independent manner, which enhances the toxicity of multiple MTAs to HCC with synergistic effect. Based on these findings, we tested a dual-mitotic suppression strategy against HCC by combining MTAs with blocking cytokinesis.

**Results**

**PRC1 is overexpressed in HCC**

Immunohistochemistry assays of 100 clinical samples were analyzed. Based on the range and intensity of H-score (H-score) of PRC1 staining, overexpressed PRC1 in both nuclei and cytoplasm was observed in HCC tissues compared to para-HCC tissues and non-malignant tissues (Table S2 and Fig. 1a, b), which is consistent with a previous report. We further analyzed data of 336 HCC and 42 non-tumor samples of patients from The Cancer Genome Atlas (TCGA), a significant upregulation of PRC1 in HCC tissues was suggested (Fig. 1c). Importantly, the overall 5-year survival rates of HCC patients with PRC1 levels above average were significantly lower than those with lower levels of PRC1 (P = 0.00163, Fig. 1d), suggesting a correlation between PRC1 upregulation and poor prognosis.

**Reduction of PRC1 inhibits proliferation of HCC cells**

We next reduced the expression of endogenous PRC1 in HCC cells by using a cancer-specific adenoviral system (Fig. S1a). To evaluate the efficiency of Ad-shPRC1, HepG2 and Hep3B cells were infected. Forty-eight hours after infection, both the mRNA and protein levels of PRC1 were significantly reduced in HepG2, Hep3B, and HuH-7 cells (P < 0.001, Fig. S1b, c), and a concentration-dependent knockdown efficiency by Ad-shPRC1 was observed (Fig. S1b). Moreover, MTT assay results demonstrated that knockdown of PRC1 by adenoviral system significantly inhibited the viability of HepG2, Hep3B, and HuH-7 cells (Fig. 2a).

To determine the effects of PRC1 level on mitotic arrest-associated molecules, HepG2 were infected with Ad-shPRC1 or Ad-vector, or transfected with empty plasmid or plasmid carrying PRC1. Western blots confirmed the expression of fusion protein (exogenous PRC1 tagged with EGFP, band on top of the endogenous PRC1), as well as reduction of endogenous PRC1 by Ad-shPRC1 (Fig. 2b). Knockdown of PRC1 enhanced the expression of p53, a tumor suppressor that controls cell cycle; and upregulated p21, a cell cycle inhibitor downstream of p53 that controls the G1/S transition (Fig. 2b, c). Consistently, overexpression of exogenous PRC1 significantly reduced such upregulations (Fig. 2b, c). Meanwhile, cyclin D1 and D3, two G1 phase cyclins

![Fig. 1](image-url)
that promote cell cycle progression, were decreased by PRC1 knockdown, and vice versa (Fig. 2b, c). In addition, we observed the levels of cyclin D1 and phosphorylated STAT3 were both reduced following reduction of PRC1, while overexpression of PRC1 showed opposite effects (Fig. 2b, c). Notably, altered PRC1 expression did not affect cyclin B1 (Fig. 2b, c), which is an M-phase cyclin regulating the metaphase/anaphase transition, suggesting that shPRC1 possibly induces a non-metaphase mitotic arrest. Recent study suggests that in p53-null or p53-mutated cancer cells, p14ARF may partly compensate the tumor
suppressor role of p53\(^{18, 19}\). Consistently, we observed that p14ARF and cell cycle inhibitor p21 were both upregulated by shPRC1 in Hep3B (p53-null) and HuH-7 (p53-loss-of-function-mutation) cells by Ad-shPRC1 (Figs. S2a, b).

**Reducing PRC1 sensitizes HCC cells to taxol by blocking telophase**

PRC1 is a critical protein associated with cytokinesis, and its reduction cause defects in cytokinesis\(^{11, 12}\). Consequently, we determined whether shPRC1 blocks the cell cycle in HCC cells. HepG2 cells were synchronized at G2/M or M-phase, respectively, by VX-680 or nocodazole treatment (Fig. S3a). We measured the length of mitosis by checking the phosphorylation level of histone H3 (p-H3), an M-phase indicator\(^{20}\). In VX-680-induced synchronization, significantly delayed mitotic exit of cells receiving shPRC1 was observed as demonstrated by the dropped p-H3 levels (6 vs 3 h, Fig. 3a). When cells were released from the nocodazole-induced synchronization, the p-H3 level in shPRC1-treated cells dramatically went down at 4–6 h after release, much longer than the controls (within 2 h, Fig. S3b). Together, these results suggest a prolonged mitotic arrest induced by PRC1 knockdown.

SAC activation is an essential mechanism for certain MTA treatments; however, its surveillance can be evaded by some cancer cells\(^2, 10\). To explore whether SAC activation is required for shPRC1-induced growth inhibition of HCC cells, an SAC inhibitor AZ3146 was used\(^{21}\). AZ3146 showed little effect on cell viability per se, but significantly attenuated the toxicity of taxol (one of commonly used MTAs) to HepG2 cells (Fig. S3c), which was consistent with a previous report that MTAs-induced growth inhibition requires SAC activation\(^{22}\). However, the viability of cells receiving Ad-shPRC1 or Ad-shPRC1/taxol combination was unaffected by AZ3146 treatment (Fig. 3b), indicating that the suppressive function of shPRC1 is independent of SAC activation.

To demonstrate the morphology of HCC cells after PRC1 knockdown, a time-lapse microscopy analysis was performed. In shPRC1-treated HepG2 cells, multinuclear were induced and formation of apoptotic bodies followed shortly, indicating cytokinesis failure and subsequently apoptosis in these cells (Fig. S3d). Next, confocal microscopy was applied to examine the cell phase that shPRC1 suppresses. Cells rapidly entered M-phase 30 min after being released from G2/M synchronization by VX-680 (\(P < 0.05\), Fig. S3e), indicating a successful synchronization. At 8 h after releasing from synchronization, shPRC1 induced a significant increase in the number of cells arrested at telophase (shown as cytokinesis, yellow arrows, Fig. 3c, d), which were similar to the cells receiving blebbistatin, an agent that induces mitotic defects of cytokinesis (Fig. 3c, d)\(^{23}\). On the other hand, taxol and epothilone B, the latter is an MTA in clinical trials for breast and ovarian cancers\(^{24}\), mainly caused arrest at pro-metaphase/metaphase (shown as pro-metaphase, white arrows, Fig. 3c, d). Combined treatment of Ad-shPRC1 with taxol/epothilone B significantly increased the number of cells with defects in cytokinesis compared with that of taxol or epothilone B alone (\(P < 0.05\), Fig. 3c, d). Additionally, taxol, epothilone B, Ad-shPRC1 or their combinations rapidly reduced the number of cells in M-phase by VX-680 re-treatment, which induces slippage of the mitotic arrested cells as previously reported (\(P < 0.05\), Fig. 3d)\(^{25}\). Together, these results demonstrate that reducing PRC1 blocks mitotic exit at telophase, while taxol/epothilone B mainly suppress mitosis at metaphase.

Some cancer cells, such as HCC, can exit mitotic arrest by prematurely entering anaphase to survive anti-mitotic therapy\(^{26}\). Consequently, we propose that a dual-mitotic suppression approach, which blocks mitosis at both metaphase and telophase using a taxol/Ad-shPRC1 combination, should bring synergistic effects against HCC. To test this hypothesis, the efficacy of combined taxol/Ad-shPRC1 treatment was investigated. MTT assays indicated that the taxol/Ad-shPRC1 combination resulted in significantly enhanced cytotoxicity compared with taxol or Ad-vector alone (Fig. 3e); while over-expression of PRC1 significantly protected the HepG2 cells from taxol (\(P < 0.001\), Fig. S3f), suggesting that PRC1 plays a critical role in the toxicity of taxol to HCC cells. Moreover, the combination index (CI) suggests the combination of shPRC1/taxol brings synergistic suppressive effects on the viability of HepG2 cells (CI = 0.486, Fig. 3f).

To further assess whether shPRC1 enhances the cytotoxicity of other mitotic drugs by blocking mitotic exit, HepG2 cells were synchronized at G2/M-phase by VX-680 and treated with taxol, epothilone B or vincristine. shPRC1 significantly increased the toxicity of all three MTAs to HCC cells (Fig. 3g); while after mitotic exit being restored by VX-680 re-administration, combined treatments reversed the decreased cell viability (\(P < 0.001\) and \(P < 0.05\), Fig. 3g). Moreover, the CI analysis also suggested a synergistic suppressive effect of the combination treatment of shPRC1 with epothilone B or vincristine on HepG2 cells (CI = 0.796 for shPRC1/epothilone B and CI = 0.650 for shPRC1/vincristine, Fig. S3g). Together, these data demonstrate that the induced MTA sensitivity of HCC cells by shPRC1 depends on blocking mitotic exit.

Since STAT3 is an oncogene reported to play a critical role in cell cycle and proliferation regulation\(^{27}\), we studied whether STAT3 activation regulates the shPRC1-induced cytokinesis block and taxol sensitivity of HCC cells. The results demonstrated that neither activation (by
interlukin-6 or epidermal growth factor nor inhibition (by cyt387 or cryptotanshinone of STAT3 phosphorylation affected shPRC1-induced cytokinesis defect or taxol sensitivity of HepG2 cells (Fig. S4a–c), which suggest that such PRC1-mediated biological functions are independent of STAT3 phosphorylation.

Fig. 3 Ad-shPRC1 enhances taxol toxicity to HCC cells by blocking mitotic exit at telophase. a The temporal variation in phosphorylated H3 after synchronization by VX-680 measured using western blots. b MTT results of indicated treatments. n = 3 independent experiments. c Representative confocal microscopy images of cells at different phases of mitosis following different treatments. Typical cell morphologies of different mitotic phases are presented at corner of top right. Blue, DAPI-stained nuclei; green, phalloidin, stained microtubules; yellow arrows, cells at cytokinesis; white arrows, cells at pro-metaphase. Magnification, ×100. d Percentage of cells arrested at telophase, pro-metaphase or M-phase under different treatments (epo, epothilone B). Results respond to three slides of each group. e Cell viability of HepG2 cells with indicated treatments using MTT assays. Value of mock-treated cells was arbitrarily set at 1. n = 3 independent experiments. f The combination index of Ad-shPRC1/taxol on HepG2 cells. g Effect of VX-680 treatment on cell growth measured by MTT assays. Value of cells receiving Ad-vector was arbitrarily set at 1. n = 3 independent experiments. Phosphorylated H3 level shown at the top-right corner. (*P < 0.05, **P < 0.01, ***P < 0.001)
Reduction of PRC1 sensitizes HCC cells to taxol through the p53 pathway

The tumor suppressor p53 plays a critical role in the development of drug resistance in cancer cells, and its accumulation during mitotic arrest triggers apoptosis following mitotic slippage. To explore whether the reduced cell viability by shPRC1 is dependent on the p53 pathway in p53-wt cells, a p53-specific inhibitor pifithrin-α was used. In addition to the Ad-vector, PRC1 reduction was also achieved by shPRC1 plasmid transfection to test the growth inhibition effects of shPRC1. The results showed that shPRC1 plasmid transfection also suppressed the viability of HepG2 cells (p53-wt) (Fig. 4a), while pifithrin-α attenuated the viability suppression of HepG2 cells by shPRC1 plasmid (Fig. 4a). Notably, the toxicity of the taxol/Ad-shPRC1 combination on HepG2 cells was also markedly reduced by pifithrin-α (Fig. 4b), suggesting that shPRC1 suppresses the p53-wt HCC cells in a p53-dependent manner.

Similar to our findings using Ad-shPRC1, PRC1 reduction by shPRC1 plasmid transfection also induced cell growth inhibition of Hep3B and HuH-7 cell lines (Fig. 4c, d). Since p14ARF may partially substitute for p53 in inhibiting the proliferation of p53-null and p53-mutant cancer cells as described above, we hypothesized that reduction of cell viability by shPRC1 in p53-null/mutant cells may depend on p14ARF. As expected, we observed a decreased cytotoxicity of shPRC1 plasmid to Hep3B and HuH-7 cells in double knockdown cells (p14-shRNA + shPRC1 plasmids) compared to shPRC1 plasmid per se (Fig. 4c, d). In addition, reduction of p14ARF significantly restored the viability of Hep3B cells receiving Ad-shPRC1/taxol combined treatment (P < 0.001, Fig. 4e), suggesting that p14ARF plays a critical role in the tumor suppressor role of shPRC1 in p53-null/mutant HCC cells.
To further study the role of p53/p14ARF in shPRC1-induced mitotic arrest, we reduced PRC1 in HepG2 and Hep3B cells respectively and restored mitotic exit by VX-680 re-administration. The results showed that shPRC1-induced mitotic arrest led to upregulation of p53/p14ARF; however, when the cells were released from mitotic arrest, the levels of p53/p14ARF significantly reduced even in the presence of shPRC1 (Fig. S4d). Similarly, foreign PRC1, which boosted the proliferation process, downregulated p53/p14ARF, whereas subsequent treatment of the mitotic inhibitor Nocodazole significantly re-enhanced p53/p14ARF (Fig. S4e), suggesting that PRC1 affects p53/p14ARF through regulating the mitotic process.

Reducing PRC1 inhibits the growth of HCC xenografts

To test the dual-mitotic suppression strategy in vivo, subcutaneous xenograft models were used, and when the tumors reached 80 mm³ in volume, mice were randomly divided and started to receive injection. At the end point of the HepG2 xenograft experiments, the mean tumor volumes of the PBS and control Ad-vector groups were 963 ± 548 mm³ and 767 ± 392 mm³, respectively; in comparison, the mean tumor volume of Ad-shPRC1 group was 169 ± 83 mm³ (P < 0.05, Fig. 5a). In another batch of xenograft experiment, the efficacy of taxol mono-treatment was relatively low, while the mean tumor volume of the taxol/Ad-shPRC1 group was 51 ± 63 mm³, demonstrating a higher efficacy compared to taxol or Ad-shPRC1 alone (P < 0.05, Fig. 5b). To further test the potent efficacy of the dual therapy, the subcutaneous HepG2 xenografts started to receive taxol/Ad-shPRC1 when they reached 200 mm³ on average, and significant tumor regression was observed (Fig. 5c). Furthermore, to study the in vivo tumor suppressor role of shPRC1 on HCC with p53-mutant, the mouse model of HCC xenograft by HuH-7 cells was used, and the dual therapy of taxol/Ad-shPRC1 showed the best efficacy, suggesting shPRC1 increases taxol sensitivity of p53-mutant HCC cells (Fig. 5d).

Moreover, an obvious reduction of PRC1 and cleaved caspase-3 was induced by Ad-shPRC1 injection, suggesting that PRC1 knockdown results in apoptosis of HCC cells in vivo (Fig. 5e). H&E staining also revealed large areas of apoptotic cells with visible nuclear fragmentation and chromatin condensation in tumors injected with Ad-shPRC1 (arrows, Fig. 5f). Together, these results suggested that reducing PRC1 has a strong anti-cancer effect against both p53-wt and p53-mutant HCCs in vivo, especially when combined with taxol.

PRC1 knockdown inhibits orthotopic HCC xenograft development and restores hepatic function

An orthotopic HCC xenograft model was further established to study the anti-HCC effect of Ad-shPRC1 in situ. Four weeks after engraftment, all mice (6 of 6) in the control groups receiving PBS or Ad-vector developed obvious tumor nodules in the liver (arrows, Fig. 6a), and four mice from each group developed ascites (data not shown). In contrast, only one of six livers from the Ad-shPRC1 group showed visible tumor nodules (Fig. 6a), and only one mouse receiving Ad-shPRC1 treatment developed ascites. To further
evaluate whether reducing PRC1 protects hepatic function, blood samples were collected and analyzed. Eighteen days after Ad-shPRC1 injections, the abnormal aspartate transaminase (AST) and albumin (ALB) levels caused by the HCC xenograft were restored (Fig. 6b).

**Discussion**

SAC activation is critical for MTAs to suppress mitosis, whereas drug-resistant cancer cells can exit mitosis by prematurely entering anaphase to evade SAC (Fig. 6c). Reducing PRC1, which blocks cytokinesis at telophase, may target the cells escaping from the metaphase arrest.
brings synergistic antitumor effects to MTAs treatment (Fig. 6c). With this rationale, we developed a dual-mitotic suppression approach that blocks mitotic exit at both metaphase and telophase using a combination of taxol and shPRC1. Our results suggest that this strategy provides excellent antitumor effects against HCC both in vitro and in vivo.

Evidence suggests that proteins involved in spindle assembly are connected with the sensitivity of cancer cells to MTAs. For example, upregulation of KIFC3 and MCAK, which are microtubule-binding molecular motors, represents MTA resistance of breast cancer. Moreover, in addition to microtubule-binding proteins that affect SAC, some cytokinesis-associated proteins or agents may also enhance the efficacy of MTAs. For instance, mulberry water extract acts synergistically with taxol triggering cytokinesis defects and subsequently apoptosis in bladder cancer cell. However, whether cytokinesis is responsible for the enhanced cytotoxicity is unknown. Here we demonstrate that reducing PRC1 enhances HCC sensitivity to MTAs through blocking cytokinesis. Our work raises the possibility that in addition to the known spindle-associated proteins, proteins essential for cytokinesis may also serve as novel antitumor targets. It will be interesting to study whether these agents are also potential candidates for treating MTA-resistant cancers.

In addition to cytokinesis and SAC, a number of mitotic components that function at different cell cycle phases have been suggested as targets for cancer therapy. For example, a therapy targeting CDK1/2, which has entered clinical trials to treat colon cancer and acute leukemia, abrogates G2/M transition and induces G2 suppression; tetraploidy checkpoint and hippo tumor suppressor pathway determine the fate of mitotic slipped cells at G1 phase. Since these regulators function in a broad range of cancers, we propose that simultaneously triggering multiple checkpoints of different mitotic phases may achieve good outcomes. Here a combinatorial HCC therapy was tested as a proof of concept, it will be interesting to test other resistant cancers, such as breast and colon cancers, with this strategy.

Materials and methods

Cell lines and tissue specimens

Human hepatocellular carcinoma cell lines Hep3B, HepG2, HuH-7 were obtained from the Cell Bank of Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) or China Center for Type Culture Collection (Wuhan, China). HEK293 (human embryonic kidney cell line) was obtained from Microbix Biosystems Inc. (Toronto, Ontario, Canada). Cell lines were grown in Dulbecco’s modified Eagle’s medium (GIBCO BRL, Grand Island, NY) supplemented with 10% FBS as previously described. Human samples, including 14 non-malignant liver diseases (cirrhosis, cholecystolithiasis, hepatapostema, cholangitis, and cavernous hemangioma) and 50 HCC and 36 adjacent tissues were obtained from Union Hospital, Tongji Medical College of Huazhong University of Science and Technology (Wuhan, China). The protocol for acquisition of tissue specimens was approved by the Institutional Review Board of Union Hospital; human sample collection procedures were in accordance with the established guidelines.

Information for plasmids used in the present study

To produce shRNAs in mammalian cells, we used a previously developed system. Based on the shRNA targeting sequence in the coding region of the human PRC1 gene, two single-strand oligonucleotides were designed and coded as follows: shPRC1 Forward: 5’-GCATATCGTGTTCAAGAAGACTTCTGACAGACGGATATGCCTTTTTG-3’
shPRC1 Reverse: 5’-AATTCTAAAGGCATATCCGTCTGTCAGAAGTCTTCTTCTGACAGACGGATATGC-3’

These single-strand oligonucleotides were annealed to generate the double-stranded oligonucleotides that were cloned into the Apal (blunted) and EcoRI sites of pBS/U6, to generate the plasmid pBS/U6-shPRC1 (shPRC1 plasmid).

The plasmid for the fusion PRC1, which is tagged with EGFP with a molecular weight of 100 kD, was obtained from GeneChem Co. (Shanghai, China). shp14 plasmid is a gift from Prof. X. Liu (Shanghai Institute for Biological Sciences, Chinese Academy of Sciences).

Generation, purification, and titration of the oncolytic adenovirus (Ad)

Generation of the oncolytic Ads was performed as previously reported. Briefly, to generate Ad-shPRC1, pBS/U6-shPRC1 was digested with BamHI, and the U6-shPRC1 expression cassette was inserted into PSP-Δ55 (the shuttle plasmid). The DNA sequence of all constructs was confirmed by restriction enzyme digestion, PCR and DNA sequencing (data not shown). Ads were generated by respective homologous recombination between the shuttle plasmid and the packaging plasmid. Identification, purification, and titration (PFU/ml) of the adenovirus were performed as previously described.

RNA extraction and quantitative reverse transcription PCR (qPCR)

Total RNA was isolated from cells using Trizol (Invitrogen). Two micrograms of RNA was used to synthesize
the first single-strand cDNA using RevertAid™ First Strand cDNA Synthesis Kit (Fermentas, Vilnius, Lithuania) as previously reported43, 44. Relative quantification of PRC1 in cells was determined using a Bio-Rad CFX96™ Real-Time PCR Detection System with Power SYBR® Green PCR Master Mix (Applied Biosystems, Carlsbad, CA). GAPDH was used as an internal standard. The following primers were used:

For PRC1: Forward: 5′-ACA GAC AGA GAC AGA GAT G -3′; Reverse: 5′-GCC GAA TGC TAC TAT TGG -3′

For GAPDH: Forward: 5′-GCT GAA GGT CGG AGT CAA CGG A-3′; Reverse: 5′-GAG GGA TCT CGC TCC TGG TGG AAG A-3′

Immunohistochemical staining
Immunohistochemistry staining was performed and analyzed using Histo-score by two individuals through a double-blind procedure as reported45, 46.

Cell viability assays
The MTT and trypan blue staining assays were performed using standard procedures as we previously reported16.

Cell synchronization
Cells were treated with 150 nM of VX-680 or 2 nM of nocodazole for 16 h (−16 h); the Ads were added to the media at 8 h before the completion of synchronization (−8 h); 8 h later, fresh VX-680/nocodazole-free media with or without taxol/epothilone B/vincristine replaced the media to release the cells from synchronization (0 h). To re-induce mitotic exit, 2 or 3 h after releasing from synchronization (2 h/3 h), the cells were re-treated with VX-68025.

Determination of synergism
Synergism was determined using the software package CalcuSyn (Biosoft, Cambridge, UK). A combination index (CI) less than 0.9 was defined as synergism.

Western blot
Western blots were performed with standard procedures as previously reported47, 48, and antibody information is provided in Table S1 of the Supplementary Material.

In vitro nuclei and microtubules staining
Cells were seeded on glass cover slips, and 24 h later they were infected with Ads at MOI of 1. Cells were then fixed with 4% paraformaldehyde, and co-stained with Phalloidin Alexa Fluor 555 (Molecular Probes, Eugene, OR, USA) and DAPI (Sigma-Aldrich, St. Louis, MO, USA). Cells were observed using a Leica TCS SP2 confocal microscope (Leica Microsystems, Wetzlar, Germany).

Animal experiments
Animal experiments were performed according to the Guide for the Care and Use of Laboratory Animals set forth by the Huazhong University of Science and Technology. Male BALB/c nude mice (4-week-old) were purchased from the Beijing HFK Bioscience (Beijing, China).

For subcutaneous xenograft model, 2×10^6 HepG2 or HuH-7 cells were subcutaneously injected into the right flank of each mouse. When tumors reached 80 mm^3 or 200 mm^3 in volume, mice were randomly divided (six mice per group). 2×10^6 PFUs of Ads per mouse or PBS (for control group) were injected into the tumor once every 2 days, for 4 times. Twenty-four hours after the first injection of Ads, some mice received taxol (6 mg/kg body weight intraperitoneal injection, twice a week for 2 weeks). Tumor volume was measured every 3 days and calculated as the length (mm) × width (mm) × depth/2 (mm) as previously reported39.

For orthotopic HCC xenograft model, 5×10^5 HepG2 cells were injected into the right liver lobe in situ, and the mice were subsequently divided (six mice per group) randomly. 2×10^7 PFUs per day of Ad-vector or Ad-shPRC1 were administrated via tail vein for four times that began at the seventh day after cells implantation. Mice were sacrificed 3 weeks after adenovirus delivery, and blood samples were collected and analyzed for AST and ALB using a BN ProSpec System (Siemens, Germany).

Statistics
All data are expressed as the mean ± SD and were analyzed using independent sample t tests and one-way analyses of variance using SPSS Base 10.0. Results were considered statistically significant when P < 0.05.

Acknowledgements
This work was supported by the Natural Science Foundation of China (81573461, 31500981, 31471208, 31671195, and 81703552), the Natural Science Foundation of Hubei Province (2013CFB359, 2014CFA021, and 2017CFB651), the Program for HUST Academic Frontier Youth Team, Integrated Innovative Team for Major Human Diseases Program of Tongji Medical College (HUST) and the Natural Science Foundation of the Self-dependent Innovation of HUST (2016YXS144).

Authors’ contributions
XL, H.C., LM, Y.L, AP, Y.C, S.S, CL, and Y.Z. performed the experiments. XM, X-Y.L., and LZ. provided key expertise and reagents. XL, X-Y.L., and KH. designed the study and analyzed the data. XL, LZ, and KH wrote the manuscript.

Author details
1Tongji School of Pharmacy, Huazhong University of Science & Technology, Wuhan 430030, China. 2Centre for Biomedicine Research, Wuhan Institute of Biotechnology, Wuhan 430074, China. 3Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, China. 4Institute for Molecular and Cell Biology, Huazhong University of Science & Technology, Wuhan 430074, China. 5School of Public Health, Wuhan University, Wuhan 430071, China. 6Academic College of Pharmacy, Huazhong University of Science & Technology, Wuhan 430074, China.
of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China. 1The Third Hospital of Wuhan, Wuhan 430060, China. 2Tongji School of Public Health, Huazhong University of Science & Technology, Wuhan 430030, China. 3Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan 430072, China

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information accompanies this paper at https://doi.org/10.1038/s41419-018-0555-4.

Received: 14 December 2017 Revised: 28 March 2018 Accepted: 28 March 2018
Published online: 10 May 2018

References
1. Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245–1252 (2012).
2. Kavallaris, M. Microtubules and resistance to tubulin-binding agents. Nat. Rev. Cancer 10, 194–204 (2010).
3. Liu, X., Gong, H. & Huang, K. Oncogenic role of kinesin proteins and targeting kinesin therapy. Cancer Sci. 104, 651–656 (2013).
4. Gascoigne, K. E. & Taylor, S. S. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14, 111–122 (2008).
5. Orth, J. D. et al. Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate. Mol. Cancer Ther. 7, 3480–3489 (2008).
6. Kops, G. J., Weaver, B. A. & Cleveland, D. W. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat. Rev. Cancer 5, 773–785 (2005).
7. Huang, H. C., Shi, J., Orth, J. D. & Mitchison, T. J. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 16, 347–358 (2009).
8. Lacktman, K. L. et al. Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C. Nature 514, 646–649 (2014).
9. Fray, A. M. & Yamano, H. APC/C-mediated degradation in early mitosis: how to avoid spindle assembly checkpoint inhibition. Cell Cycle 5, 1487–1491 (2006).
10. McGrogan, B. T., Gilmore, B., Carney, D. N. & McCann, A. Taxanes, microtubules and chemoresistant breast cancer. Biochim. Biophys. Acta 1785, 96–132 (2008).
11. Kanekura, M. et al. Oncogenic role of MPHOSPH1, a cancer-testis antigen specific to human bladder cancer. Cancer Res. 67, 3276–3285 (2007).
12. Jiang, W. et al. PRC1: a human mitotic spindle-associated CDK substrate protein required for cytokinesis. Mol. Cell 2, 877–885 (1998).
13. Liu, X. et al. MPHOSPH1: a potential therapeutic target for hepatocellular carcinoma. Cancer Sci. 96, 6623–6634 (2014).
14. Marone, M. et al. Survival and cell cycle control in early hepatocarcinogenesis: role of bc-2, and the cyclin dependent kinase inhibitors P27 and P21. Leuk. Lymphoma 43, 51–57 (2002).
15. Lui, X. et al. MPHOSPH1: a potential therapeutic target for hepatocellular carcinoma. Cancer Res. 74, 6623–6634 (2014).
16. Marone, M. et al. Survival and cell cycle control in early hepatocarcinogenesis: role of bc-2, and the cyclin dependent kinase inhibitors P27 and P21. Leuk. Lymphoma 43, 51–57 (2002).
46. Budwit-Novotny, D. A. et al. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res. 46, 5419–5425 (1986).

47. Li, J. et al. Accumulation of endoplasmic reticulum stress and lipogenesis in the liver through generational effects of high fat diets. J. Hepatol. 56, 900–907 (2012).

48. Chen, H. et al. ELABELA and an ELABELA fragment protect against AKI. J. Am. Soc. Nephrol.: JASN 28, 2694–2707 (2017).

49. Liu, X. et al. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL. Cancer Gene Ther. 19, 49–57 (2012).